NASDAQ:KOD
Kodiak Sciences Inc. Stock News
$3.21
-0.0500 (-1.53%)
At Close: May 21, 2024
Kodiak Sciences to Present at the Jefferies Global Healthcare Conference
08:00am, Friday, 27'th May 2022
PALO ALTO, Calif. , May 27, 2022 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prev
Kodiak Sciences: Potential For Comeback After Trial Setback
09:09am, Tuesday, 17'th May 2022
Results from the BEACON study, which is using KSI-301 for the treatment of patients with retinal vein occlusion, are expected by Q3 of 2022. The global retinal vein occlusion market is estimated to be
Kodiak Sciences (KOD) Q1 Loss Widens, Eye Candidate in Focus
02:18pm, Wednesday, 11'th May 2022
Kodiak Sciences (KOD) reports wider-than-expected loss in the first quarter of 2022. Focus is on lead candidate, KSI-301, being developed for treating various retinal vascular diseases.
Should You Buy Kodiak (KOD) Ahead of Earnings?
10:32am, Friday, 06'th May 2022
Kodiak (KOD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bonds Are Screaming “Recession.” That's Great News For One Top Sector.
04:44pm, Tuesday, 29'th Mar 2022
The 10-2 year treasury yield spread is close to zero. Here's what you should do about this warning sign of a coming recession.
2 Net Current Asset Value Stocks to Consider
05:32pm, Wednesday, 23'rd Mar 2022
There are some investors who buy U.S.-listed stocks that are trading below their liquidation value because they believe there is a lot to gain in these stocks after the market reprices shares to near
2 Dirt Cheap Biotechs to Buy If You're a Contrarian
11:07am, Saturday, 05'th Mar 2022
Today's losers are selling for peanuts, and they just might become tomorrow's winners.
Kodiak Sciences (KOD) Q4 Loss Widens, Eye Candidate in Focus
11:29am, Wednesday, 02'nd Mar 2022
Kodiak Sciences (KOD) reports a wider-than-expected loss for the fourth quarter of 2021. It is focusing on the lead candidate, KSI-301, being developed for treating various retinal vascular diseases.
Why Kodiak Sciences (KOD) Might Surprise This Earnings Season
09:57am, Wednesday, 02'nd Mar 2022
Kodiak Sciences (KOD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Here's Why Kodiak Sciences Inc. (KOD) is Poised for a Turnaround After Losing 82.3% in 4 Weeks
11:30am, Friday, 25'th Feb 2022
Kodiak Sciences Inc. (KOD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings
Why Kodiak Sciences Stock Is Cratering Today
04:17pm, Wednesday, 23'rd Feb 2022
A disappointing clinical trial result is weighing heavily on the drugmaker's shares today.
KOD Stock Alert: Why Is Kodiak Sciences Plunging 80% Today?
03:16pm, Wednesday, 23'rd Feb 2022
Disappointing drug trial results have sent Kodiak Sciences and shares of KOD stock plunging more than 80% in today's trading session. The post KOD Stock Alert: Why Is Kodiak Sciences Plunging 80% Toda
Palo Alto Is Leading the Nasdaq Higher, but 1 Biotech Is Getting Crushed Wednesday
09:01am, Wednesday, 23'rd Feb 2022
Investors are trying to take a longer-term view on the geopolitical situation.
Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter
08:00am, Tuesday, 15'th Feb 2022
KSI-301 has shown higher retinal bioavailability and longer half-life than the comparator for this Phase 3 trial, the blockbuster drug Eylea (Aflibercept).
Read Why Barclays Analyst Is 'Negatively Biased' On Kodiak Sciences
12:29pm, Monday, 07'th Feb 2022
Barclays has lowered the firm's price target on Kodiak Sciences Inc KOD to $50 from $81 and keeps an Underweight rating on the shares, representing an almost 20% downside. Get the Inside Access T
